← Back to Search

Atypical Antipsychotic

Antipsychotics for Lewy Body Disease (CAMELOT Trial)

Phase 4
Recruiting
Led By Sarah Horn, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

CAMELOT Trial Summary

This trial will compare two drugs to see which works better to reduce hallucinations & delusions caused by PD or DLB (Lewy body disease).

Who is the study for?
This trial is for individuals with hallucinations or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB), who need to start antipsychotic treatment. Participants must be seen at the UT Health San Antonio neurology clinic and have a doctor willing to manage both Pimavanserin and Quetiapine treatments.Check my eligibility
What is being tested?
The study aims to compare the effectiveness of two antipsychotic medications, Pimavanserin and Quetiapine, in improving psychosis symptoms in patients with Lewy body disease over time when used in routine clinical practice.See study design
What are the potential side effects?
Pimavanserin may cause swelling of the legs, nausea, and confusion. Quetiapine can lead to drowsiness, weight gain, dry mouth, constipation, or blurred vision. Side effects vary from person to person.

CAMELOT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Delusions
Secondary outcome measures
CGIC, PGIC, CGI-C:CVR
MDS-UPDRS part 3
Mortality
+5 more
Other outcome measures
Pharmaceutical Preparations
NPI-Q caregiver portion
Patient contact

CAMELOT Trial Design

2Treatment groups
Active Control
Group I: quetiapineActive Control1 Intervention
Elderly patients with dementia-related psychosis will be treated with quetiapine, an atypical antipsychotic indicated for the treeatment of: schizophrenia, bipolar I manic episodes and bipolar depressive episodes.
Group II: pimavanserinActive Control1 Intervention
Elderly patients with dementia-related psychosis will be treated with pimavanserin, an atypical antipsychotic indicated for treatment of hallucinations and delusions associated with Parkinson's disease.

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
452 Previous Clinical Trials
91,320 Total Patients Enrolled
5 Trials studying Dementia
2,107 Patients Enrolled for Dementia
Alzheimer's AssociationOTHER
90 Previous Clinical Trials
40,679 Total Patients Enrolled
32 Trials studying Dementia
32,394 Patients Enrolled for Dementia
Sarah Horn, MDPrincipal InvestigatorUniversity of Texas Health Science Center San Antonio

Media Library

Pimavanserin (Atypical Antipsychotic) Clinical Trial Eligibility Overview. Trial Name: NCT05590637 — Phase 4
Dementia Research Study Groups: quetiapine, pimavanserin
Dementia Clinical Trial 2023: Pimavanserin Highlights & Side Effects. Trial Name: NCT05590637 — Phase 4
Pimavanserin (Atypical Antipsychotic) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05590637 — Phase 4

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent does quetiapine pose potential risks to patients?

"Quetiapine's safety has been rigorously tested, so it is given a score of 3. This drug was recently approved in its fourth stage of development."

Answered by AI

How many research participants are enrolled in this clinical investigation?

"Affirmative. Clinicaltrials.gov attests to this medical trial's active recruitment status, which began on April 22nd 2022 and was recently updated on October 18th 2022. Ninety-four participants are needed from a single location for the study to be completed successfully."

Answered by AI

Are recruitment efforts still underway for this research?

"Affirmative. Evidence on clinicaltrials.gov confirms that this medical examination, which was originally advertised on April 22nd 2022, is actively enrolling individuals into the study. Approximately 94 participants must be registered from 1 location."

Answered by AI

Who else is applying?

What state do they live in?
Louisiana
How old are they?
65+
What site did they apply to?
UT Health Science Center - San Antonio
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Comparing Antipsychotic Medications in LBD Over Time
Sarah Horn 2022. "Comparing Antipsychotic Medications in LBD Over Time". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05590637.
All > Dementia With Lewy Bodies > Seroquel
~16 spots leftby Oct 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top